Contineum Therapeutics, Inc. (CTNM)
(Delayed Data from NSDQ)
$20.77 USD
-0.23 (-1.10%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $20.60 -0.17 (-0.82%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTNM 20.77 -0.23(-1.10%)
Will CTNM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTNM based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CTNM
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics Welcomes Sarah Boyce to Board
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary